CL Clenbuterol

Indications:

For prolonged treatment of bronchospastic
syndrome in mild and moderate atopic and non-atopic bronchial asthma;
strain-induced bronchospasm; in the complex therapy of chronic spastic
bronchitis and COPD.

Dosage and administration:

Adults: 0,02 mg orally, morning
and evening; Maintenance dose 0,01 mg 2 times daily. In more serious
conditions, 0,04 mg, 2 times daily (morning and evening) should be
administered in the first days. The dose should be reduced upon
condition improving. In children: 6-12 years 1/2 tablet 2 times daily.
Over 12 years 1/2 tablet 2-3 times daily or 1 tablet 2 times daily.

Contraindications:

Hypersensitivity to the product;
thyrotoxicosis; digitalis intoxication, tachycardia, tachyarrhythmia,
hyperthrophic obstructive cardiomyopathy; first trimester of pregnancy.

Drug interactions:

Beta-blockers antagonize Clenbuterol effects. In concomitant
administration with antidiabetics, their dose should be increased due to
glycogenolysis stimulation by Clenbuterol. Co-administration with
cardiac glycosides, MAO-inhibitors and theophylline may cause heart
rhythm disorders.

The effect of Clenbuterol is potentiated by tricyclic antidepressants,
some antihistamines and levothyroxin and reduced by some
antihypertensive products (guanethidine). Halothane and other
halogenated hydrocarbon anesthetics and cyclopropane sensitize
myocardium and may potentiate the arrhythmogenic effect of ?2-
sympathomimetics.

Adverse reactions:

Insomnia, headache, hyperkinesias, psychic disorders, reddening,
sweating, tremor and anxiety, excitability, dizziness; the patients with
Parkinsons syndrome may feel increase of tremor and muscle rigidity;
palpitations, tachycardia, reduction or, rarely, rise of blood pressure;
urine retention; paradoxical bronchospasm which requires immediate
discontinuation of therapy. In patients with diabetes mellitus,
hyperglycaemia may develop. The manifestation of such adverse reactions
requires dose reduction without need of therapy termination, because
they fade within 1-2 weeks after therapy initiation. In prolonged
administration, tachyphyllaxis to Clenbuterol may be observed, but
sensitivity is restored after discontinuation of therapy.

Supplied:

50 tablets of 0,02 mg.

Dispensing:

On doctors prescription.